{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443967832
| IUPAC_name = 8S,9S,10R,11R,13S,14S,17S)-11,17-dihydroxy-10,13,17-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-2-carbaldehyde
| image = Formebolone.png
| alt = Skeletal formula of formebolone
| width = 250
| image2 = Formebolone 3D ball.png
| alt2 = Ball-and-stick model of the formebolone molecule
| width2 = 250

<!--Clinical data-->
| tradename = Esiclene, Hubernol, Metanor
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 2454-11-7
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 17150
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 16234
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Z2MMV08KUQ
| KEGG = 
| ChEBI = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2107419

<!--Chemical data-->
| C=21 | H=28 | O=4
| molecular_weight = 344.44 g/mol
| SMILES = C[C@@]1(CC[C@@H]2[C@@]1(C[C@H]([C@H]3[C@H]2CCC4=CC(=O)C(=C[C@]34C)C=O)O)C)O
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C21H28O4/c1-19-9-12(11-22)16(23)8-13(19)4-5-14-15-6-7-21(3,25)20(15,2)10-17(24)18(14)19/h8-9,11,14-15,17-18,24-25H,4-7,10H2,1-3H3/t14-,15-,17+,18+,19-,20-,21-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = AMVODTGMYSRMNP-GNIMZFFESA-N
| synonyms = Formyldienolone; 2-Formyl-11α-hydroxy-17α-methyl-δ<sup>1</sup>-testosterone
}}

'''Formebolone''' ([[International Nonproprietary Name|INN]], [[British Approved Name|BAN]]) (brand names '''Esiclene''', '''Hubernol''', '''Metanor'''), also known (confusingly) as '''formyldienolone''', as well as '''2-formyl-11α-hydroxy-17α-methyl-δ<sup>1</sup>-testosterone''', is an [[oral administration|orally active]] [[anabolic-androgenic steroid]] (AAS) described as an [[anticatabolic]] and [[anabolic drug|anabolic]] [[drug]] that is or has been marketed in [[Spain]] and [[Italy]].<ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA471|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=471–}}</ref><ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA577%7Cdate%3D14+November+2014%7Cpublisher%3DSpringer%7Cisbn%3D978-1-4757-2085-3%7Cpages%3D577%E2%80%93%7D%7D%3C%2Fref%3E|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=577–}}</ref><ref name="MortonHall1999">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=mqaOMOtk61IC&pg=PA125|date=31 October 1999|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=125–}}</ref> As an AAS, it shows some anabolic activity, though it is inferior to [[testosterone]] in terms of [[potency (pharmacology)|potency]], but is said to have virtually no [[androgen]]ic activity.<ref name="pmid799985">{{cite journal |vauthors=Gelli D, Vignati E |title=Metabolic studies with formebolone (2-formyl-17 (alpha)-methyl-androsta-1,4-diene-11 (alpha), 17 (beta)-diol-3-one) in humans |journal=J. Int. Med. Res. |volume=4 |issue=2 |pages=96–105 |year=1976 |pmid=799985 |doi= 10.1177/030006057600400203|url=}}</ref> Formebolone counteracts the [[catabolic]] effects (control of [[nitrogen balance]]) of potent [[glucocorticoid]]s like [[dexamethasone phosphate]].<ref name="pmid799985" /><ref name="pmid1036699">{{cite journal |vauthors=Cerutti S, Forlani A, Galimberti E |title=Anticatabolic action of formebolone in the castrated rat treated with dexamethasone |journal=Arzneimittelforschung |volume=26 |issue=9 |pages=1673–7 |year=1976 |pmid=1036699 |doi= |url=}}</ref> A close [[structural analog|analogue]], [[roxibolone]] (and its long-acting [[ester]] variant [[decylroxibolone]]), shows similar antiglucocorticoid activity to formebolone but, in contrast, is devoid of activity as an AAS.<ref name="pmid6523544">{{cite journal |vauthors=Felippone F, Resnati G, Scolastico C, Tronconi G |title=Synthesis of 2-carboxy-11 beta, 17 beta-dihydroxy-17-methyl-1, 4-androstadien-3-one and related compounds |journal=Steroids |volume=43 |issue=3 |pages=271–82 |year=1984 |pmid=6523544 |doi= 10.1016/0039-128x(84)90045-x|url=}}</ref>

Roxibolone has been found not to bind to the [[glucocorticoid receptor]], and it has been suggested that the antiglucocorticoid activity of roxibolone and formebolone may instead be mediated by [[enzyme modulator|modulation]] of [[enzyme|enzymatic]] processes.<ref name="pmid6970661">{{cite journal |vauthors=Dahlberg E, Snochowski M, Gustafsson JA |title=Regulation of the androgen and glucocorticoid receptors in rat and mouse skeletal muscle cytosol |journal=Endocrinology |volume=108 |issue=4 |pages=1431–40 |year=1981 |pmid=6970661 |doi=10.1210/endo-108-4-1431 |url=}}</ref> Indeed, [[11α-Hydroxyprogesterone|11α-]] and [[11β-hydroxyprogesterone]] (formebolone and roxibolone being 11α- and 11β-hydroxylated (respectively) similarly) are known to be potent [[enzyme inhibitor|inhibitor]]s of [[11β-hydroxysteroid dehydrogenase]] (11β-HSD), which is responsible for the [[biosynthesis]] of the potent [[endogenous]] glucocorticoids [[cortisol]] and [[corticosterone]] (from the [[precursor (biochemistry)|precursor]]s [[deoxycortisol]] and [[deoxycorticosterone]], respectively).<ref name="pmid7895695">{{cite journal | vauthors = Souness GW, Latif SA, Laurenzo JL, Morris DJ | title = 11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat | journal = Endocrinology | volume = 136 | issue = 4 | pages = 1809–12 | year = 1995 | pmid = 7895695 | doi = 10.1210/endo.136.4.7895695 | url = }}</ref><ref name="pmid8698448">{{cite journal | vauthors = Souness GW, Morris DJ | title = 11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat | journal = Hypertension | volume = 27 | issue = 3 Pt 1 | pages = 421–5 | year = 1996 | pmid = 8698448 | doi = 10.1161/01.hyp.27.3.421| url = }}</ref> However, formebolone was found to be a very weak inhibitor of [[Corticosteroid 11-beta-dehydrogenase isozyme 2|11β-HSD type 2]] ([[IC50|IC<sub>50</sub>]] > 10 μM), although this specific [[isoenzyme]] of 11β-HSD is responsible for the inactivation of glucocorticoids rather than their production.<ref name="pmid22273746">{{cite journal |vauthors=Fürstenberger C, Vuorinen A, Da Cunha T, Kratschmar DV, Saugy M, Schuster D, Odermatt A |title=The anabolic androgenic steroid fluoxymesterone inhibits 11β-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation |journal=Toxicol. Sci. |volume=126 |issue=2 |pages=353–61 |year=2012 |pmid=22273746 |doi=10.1093/toxsci/kfs022 |url=}}</ref>

==References==
{{Reflist|2}}

{{Androgens and antiandrogens}}
{{Androgen receptor modulators}}

[[Category:Antiglucocorticoids]]
[[Category:Androgens and anabolic steroids]]
[[Category:Androstanes]]
[[Category:Aldehydes]]
[[Category:Alcohols]]
[[Category:Hepatotoxins]]
[[Category:Ketones]]
[[Category:World Anti-Doping Agency prohibited substances]]


{{steroid-stub}}
{{genito-urinary-drug-stub}}